Donald Heald, Ph.D.
Dr. Heald brings to Biosion over 35 years of clinical pharmacology and translational science experience in the pharmaceutical and biotech industries.
Before joining Biosion, Dr. Heald worked at Janssen Biotherapeutics (J&J) as Head of Discovery Translational Sciences and his group was responsible for determining the First in Human starting dose and predicting an efficacious dose for biologics across multiple therapeutic areas. Prior to Janssen Biotherapeutics, He served as Vice President and Global Head of Clinical Pharmacology at J&J R&D and his group was responsible for conducting clinical pharmacology Phase 1-4 studies for all drug candidates in all therapeutic areas and global regulatory submissions. He also led the Clinical Drug Disposition group at Rhone Poulenc Rorer, was a Sr. Scientist at The Upjohn Company and served as a Clinical Pharmacologist in the Cardio/Renal Division at the FDA.
Dr. Heald holds an Ph.D. in Pharmaceutical Sciences from West Virginia University.